A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis: Substance Use and Misuse

Substance Use and Misuse

Volumn 54, Issue 4, 2019, Pages 549-559

  Voce, Alexandra ^a   Calabria, Bianca ^b,c   Burns, Richard ^a   Castle, David ^d,e   McKetin, Rebecca ^c,f  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CURTIN UNIVERSITY   (Australia)

Author keywords

Amphetamine; clinical presentation; duration; persistent; stimulants; substance induced psychotic disorder

Indexed keywords

METHAMPHETAMINE;

AMPHETAMINE DEPENDENCE; COMPLICATION; HUMAN; PSYCHOLOGY; PSYCHOSIS;

AMPHETAMINE-RELATED DISORDERS; HUMANS; METHAMPHETAMINE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 85060934438     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826084.2018.1521430     Document Type: Article

References (56)

1. Altemus, M., Sarvaiya, N., & Epperson, C. (2014). Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrinol, 35(3), 320–330.
2. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, Five Edition. Arlington, VA: Author.
3. Andreasen, N. (1983). The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa.
4. Andreasen, N. (1984). The scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa.
5. Angrist, B., & Gershon, S. (1970). The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biological Psychiatry, 2, 95–107.
6. Arunogiri, S., Foulds, J., Mcketin, R., & Lubman, D. (2018). A systematic review of risk factors for methamphetamine-associated psychosis. Australian & New Zealand Journal of Psychiatry, 52(6), 514–529.
7. Bell, D. (1965). Comparison of amphetamine psychosis and schizophrenia. The British Journal of Psychiatry: The Journal of Mental Science, 111, 701–707.
8. Bell, D. (1973). The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry, 29(1), 35–40.
9. Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., … Franck, J. (2012). Amphetamine-induced psychosis: A separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 12, 221
10. Chen, C.-K., Lin, S.-K., Chen, Y.-C., Huang, M.-C., Chen, T.-T., Ree, S. C., & Wang, L.-J. (2015). Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug and Alcohol Dependence, 148, 158–164.
11. Chen, C.-K., Lin, S.-K., Sham, P. C., Ball, D., Loh, E.-W., Hsiao, C.-C., … Murray, R. M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine, 33(8), 1407–1414.
12. Chen, C., Lin, S., Sham, P., Ball, D., Loh, W., & Murray, R. (2005). Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 136B(1), 87–91.
13. Chinese Medical Association (2004). Chinese Classification and Diagnostic Criteria of Mental Disorder. 3rd ed. Jinan: Shandong Science and Technology Press.
14. Cho, A., & Melega, W. (2002). Patterns of methamphetamine abuse and their consequences. Journal of Addictive Diseases, 21(1), 21–34.
15. Connell, P. (1958). Amphetamine psychosis. London: Oxford Press.
16. Cooper, L., Peters, L., & Andrews, G. (1998). Validity of the Composite International Diagnostic Interview (CIDI) psychosis module in a psychiatric setting. Journal of Psychiatric Research, 32(6), 361–368.
17. Darke, S., Kaye, S., McKetin, R., & Duflou, J. (2008). Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review, 27(3), 253–262.
18. Ellinwood, E. (1967). Amphetamine psychosis. I. Description of the Individuals and Process. Journal of Nervous and Mental Disease, 144(4), 273–283.
19. Fasihpour, B., Molavi, S., & Shariat, S. (2013). Clinical features of inpatients with methamphetamine-induced psychosis. Journal of Mental Health (Abingdon, England), 22(4), 341–349.
20. First, M., Spitzer, R., Gibbon, M., & Williams, J. (2002). Structured Clinical Interview for DSM-IV, Research Version. New York: New York State Psychiatric Institute.
21. Foussias, G., Agid, O., Fervaha, G., & Remington, G. (2014). Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders. European Neuropsychopharmacology, 24(5), 693–709.
22. Glasner-Edwards, S., Mooney, L., Marinelli, C., P., Hillhouse, M., Ang, A., & Rawson, R. (2014). Methamphetamine psychosis: Epidemiology and management. CNS Drugs, 28(12), 1115–1126.
23. Grant, K., LeVan, T., Wells, S., Li, M., Stoltenberg, S., Gendelman, H., … Bevins, R. (2012). Methamphetamine-associated psychosis. Journal of Neuroimmune Pharmacology, 7(1), 113–139.
24. Hartley, S., Barrowclough, C., & Haddock, G. (2013). Anxiety and depression in psychosis: A systematic review of associations with positive psychotic symptoms. Acta Psychiatrica Scandinavica, 128(5), 327–346.
25. Iwanami, A., Sugiyama, A., Kuroki, N., Toda, S., Kato, N., Nakatani, Y., … Kaneko, T. (1994). Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. Acta Psychiatrica Scandinavica, 89(6), 428–432.
26. Javadian, S., Shabani, A., & Shariat, S. (2016). Clinical course of methamphetamine-induced psychotic disorder in a 3-month follow-up. Prim Care Companion CNS Disord, 18(6). doi: 10.1016/j.jsat.2007.12.004
27. Jonsson, L., & Sjostrom, K. (1970). A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis. British Journal of Psychiatry, 117(541), 661–665.
28. Kay, S., Fiszbein, A., & Opler, L. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.
29. Kittirattanapaiboon, P., Mahatnirunkul, S., Booncharoen, H., Thummawomg, P., Dumrongchai, U., & Chutha, W. (2010). Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review, 29(4), 456–461.
30. Koreen, A., Lieberman, J., Alvir, J., Mayerhoff, D., Loebel, A., Chakos, M., … Cooper, T. (1993). Depression in first-episode schizophrenia. American Journal of Psychiatry, 9(2-3), 240–1648.
31. Leamon, M., Flower, K., Salo, R., Nordahl, T., Kranzler, H., & Galloway, G. (2010). Methamphetamine and paranoia: The methamphetamine experience questionnaire. The American Journal on Addictions, 19(2), 155–168.
32. Mahoney, J., Hawkins, R., De La Garza, R., Kalechstein, A., & Newton, T. (2010). Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gender Medicine, 7(5), 414–421.
33. Martin, W., Sloan, J., Sapira, J., & Jasinski, D. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology & Therapeutics, 12(2part1), 245–258.
34. McKetin, R., Baker, A., Dawe, S., Voce, A., & Lubman, D. (2017). Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Research, 251, 349–354.
35. McKetin, R., Dawe, S., Burns, R. A., Hides, L., Kavanagh, D. J., Teesson, M., … Saunders, J. B. (2016a). The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug and Alcohol Dependence, 161, 104–109.
36. McKetin, R., Gardner, J., Baker, A. L., Dawe, S., Ali, R., Voce, A., … Lubman, D. I. (2016b). Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Research, 238, 166–171.
37. McKetin, R., Lubman, D., Baker, A., Dawe, S., & Ali, R. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry, 70(3), 319–324.
38. McKetin, R., Lubman, D., Najman, J., Dawe, S., Butterworth, P., & Baker, A. (2014). Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction, 109(5), 798–806.
39. McKetin, R., McLaren, J., & Kelly, E. (2005). The Sydney methamphetamine market: Patterns of supply, use, personal harms and social consequences. The National Drug Law Enforcement Research Fund Monograph series (no.13). Syndey, New South Wales: National Drug and Alcohol Research Centre.
40. McKetin, R., McLaren, J., Lubman, D., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. Addiction, 101(10), 1473–1478.
41. McKetin, R., McLaren, J., Lubman, D., & Hides, L. (2008). Hostility among methamphetamine users experiencing psychotic symptoms. American Journal on Addictions, 17(3), 235–240.
42. Medhus, S., Rognli, E., Gossop, M., Holm, B., Mørland, J., & Bramness, J. (2015). Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. The American Journal on Addictions, 24(7), 586–589.
43. Niemi-Pynttäri, J., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K., & Pirkola, S. (2013). Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 finnish inpatient cases. The Journal of Clinical Psychiatry, 74(01), e94–e99.
44. Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophrenia Research and Treatment, 2012, 1–198.
45. Overall, J., & Gorham, J. (1962). The brief psychiatric rating scale. Psychological Reports, 10(3), 799–812.
46. Rosay, A., Skroban Najaka, S., & Herz, D. (2007). Differences in the validity of self-reported drug use across five factors: Gender, race, age, type of drug, and offense seriousness. Journal of Quantitative Criminology, 23(1), 41–58.
47. Sato, M., Chen, C., Akiyama, K., & Otsuki, S. (1983). Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biological Psychiatry, 18, 429–440.
48. Sheehan, D., Lecrubier, Y., Sheehan, K., Amorim, P., Janavs, J., & Weiller, E. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22–33.
49. Srisurapanont, M., Arunpongpaisal, S., Wada, K., Marsden, J., Ali, R., & Kongsakon, R. (2011). Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(4), 959–964.
50. Tandon, R., Nasrallah, H., & Keshavan, M. (2009). Schizophrenia, “Just the facts” 4. Clinical features and conceptualization. Schizophrenia Research, 110(1–3), 1–23.
51. Tomiyama, G. (1990). Chronic schizophrenia-like states in methamphetamine psychosis. Psychiatry and Clinical Neurosciences, 44(3), 531–539.
52. Tsuang, M., Simpson, J., & Kronfol, Z. (1982). Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Archives of General Psychiatry, 39(2), 141–147.
53. United Nations Office on Drugs and Crime (2016). World drug report. New York: United Nations.
54. van Os, J., (2014). The many continua of psychosis. JAMA Psychiatry, 71, 985–986.
55. World Health Organization. (1992). ICD-10 Classification of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: Author.
56. Yeh, H., Lee, Y., Sun, H., & Wan, S. (2001). Six months follow-up of patients with methamphetamine psychosis. Chinese Medical Journal, 64, 388–394.